期刊文献+

奥美沙坦酯对慢性心力衰竭小鼠的保护作用 被引量:3

The Protective Effect of Olmesartan Medoxomil on Chronic Heart Failure in Mice
暂未订购
导出
摘要 目的:观察奥美沙坦酯对慢性心力衰竭小鼠的保护作用。方法:健康C57小鼠随机分为假手术组(SHAM组)、慢性心力衰竭组(CHF组)和奥美沙坦酯治疗组(OLM组)。以冠状动脉左前降支结扎法建立慢性心力衰竭小鼠模型,其中OLM组以10mg/kg剂量每日胃饲,4周时观察各组小鼠心率、血压及一般状况,检测血浆和心脏血管紧张素(Ang)Ⅱ水平;Real-timePCR法检测心脏血管紧张素Ⅱ1型受体(AT1R)、Ⅰ型胶原、Ⅲ型胶原的表达情况,AZAN染色观察心脏组织结构变化。结果:与SHAM组相比,CHF组收缩压显著增高,OLM组较CHF组显著降低(P<0.05)。与SHAM组相比,CHF组血浆和心脏AngⅡ水平,AT1R和Ⅰ、Ⅲ型胶原的表达增高(P<0.05),OLM组心脏AngⅡ水平,AT1R和Ⅰ、Ⅲ型胶原的表达较CHF组均明显降低(P<0.05)。CHF组AZAN染色可见心肌组织中梗死区蓝染,心肌纤维消失,代之以纤维结缔组织,OLM组亦可见蓝染的纤维结缔组织,但与CHF组相比面积减少。结论:慢性心力衰竭可使心内肾素血管紧张素系统激活并导致心脏损伤,奥美沙坦酯通过抑制AngⅡ起到保护心脏作用。 Objective: To investigate the protective effect of olmesartan medoxomil (OLM) on chronic heart failure (CHF) in mice. Methods: C57 mice were divided into sham operation group (SHAM group), chronic heart failure grou1 (CHF group) and olmesartan medoxomil treatment group (OLM group). The experimental CHF model was established b coronary artery ligation. Mice of OLM group were fed with OLM at daily dose of 10 mg/kg. The heart rate, blood pressure plasma and cardiac angiotensin II levels were observed after four-week treatment. The cardiac angiotensin II type receptor (AT1R), expressions of type I and type III collagen were detected by real-time PCR. The cardiac pathologics changes were determined by AZAN staining. Results: Compared with SHAM group, the systolic blood pressure, plasma ant cardiac angiotensin II levels, AT1R and type I and I1[ collagen expression were significantly increased in CHF group (P 0.05), while in OLM group, they were significantly lower than those in CHF group except for the plasma angiotensin II level (P 〈 0.05). AZAN stain showed that blue-stained myocardial infarction was in CHF group, the myocardial fibers were disappear and replaced by fibrous connective tissue. There was blue-stained fibrous connective tissues in OLM group, bu the area was reduced compared with that of CHF group. Conclusion: Chronic heart failure can activate the intracardiac renin-angiotensin system, leading to heart damage. Olmesartan medoxomil can protect heart by inhibiting effects o angiotensin II.
出处 《天津医药》 CAS 北大核心 2012年第9期916-918,I0001,共4页 Tianjin Medical Journal
基金 国家自然科学基金资助项目(项目编号:81100109)
关键词 心力衰竭 血管紧张素Ⅱ 受体 血管紧张素 1型 胶原Ⅰ型 胶原Ⅲ型 小鼠 近交C57BL 奥美沙坦酯 heart failure angiotensin II receptor, angiotensin, type 1 collagen type I collagen type III mice,inbred C57BL Olmesartan
  • 相关文献

参考文献8

  • 1Mahmud H, Sillje HH, Cannon MV, et al. Regulation of the (pro) renin-renin receptor in cardiac remodeling [J].J Cell Mol Med, 2012,16(4):722-729.
  • 2Weir MR.Effects of renin-angiotensin system inhibition on endorgan protection: can we do better[J]? Clin Ther, 2007, 29(9): 1803-1824.
  • 3Bader M, Ganten D.Update on tissue renin-angiotensin systems[J].J Mol Med, 2008,86(6): 615-621.
  • 4Koike H, Sada T, Mizuno M.In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin Ⅱ type AT1 receptor antagonist[J]. J Hypertens Supp], 2001 ,19(1):S3-S14.
  • 5MeManus DD, Chinali M, Saczynski JS, et al. 30-year trends in heart failure in patients hospitalized with acute myocardial infarction[l]. Am J Cardiol, 2011,107(3):353-359.
  • 6王立军,马虹.血管紧张素转换酶2研究进展[J].中国病理生理杂志,2005,21(9):1858-1863. 被引量:5
  • 7Raizada V, Skipper B, Luo W, et al. Intracardiac and intrarenal renin-angiotensin systems: mechanisms of cardiovascular and renal effects[J]. J Investig Med, 2007,55(7):341-359.
  • 8贺明,陆利民,姚泰.肾素-血管紧张素系统在调节肾脏活动和慢性肾功能不全中的作用[J].生理科学进展,2004,35(2):188-192. 被引量:15

二级参考文献48

  • 1[1]Huang W, Gallois Y, Bouby N, et al. Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. Proc Natl Acad Sci USA,2001,98 13330~13334.
  • 2[2]Nguyen G,Delarue F,Burckle C,et al.Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin.J Clin Invest,2002,109 1417~1427.
  • 3[3]Robert M, Helmy M. The intrarenal rennin-angiotensin system and diabetic nephropathy. Trends Endocrinol Metab, 2003,14 274~281.
  • 4[4]Nishiyama A, Seth DM, Navar LG. Renal interstitial fluid concentrations of angiotensins I and Ⅱin anesthetized rats. Hypertension,2002,39 129~134.
  • 5[5]Toke A, Meyer TW. Hemodynamic effects of angiotensin II in the kidney. Contrib Nephrol,2001,135 34~46.
  • 6[6]Wolf G, Butzmann U, Wenzel U. The renin-angiotensin system and progression of renal disease: From hemodynamics to cell biology. Nephron Physiol,2003,93 3~13.
  • 7[7]Cao Z,Kelly DJ,Cox A,et al.Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis.Kidney Int,2000,58 2437~2451.
  • 8[8]Ling Y, Nancy A, Wayne A. Therapeutic strategies to halt renal fibrosis. Curr Opin Pharmacol, 2002, 2 177~181.
  • 9[9]Gaedeke J, Peters H, Nobel NA, et al. Angiotension II,TGF-β and renal fibrosis. Contrib Nephrol, 2001, 135 153~160.
  • 10[10]Mezzano S, Ruiz-Orega M, Egido J. Angiotension II and renal fibrosis. Hypertension,2001,38 635~638.

共引文献17

同被引文献32

  • 1BRAUNWALD E.心脏病学[M].陈灏珠,译.北京:人民卫生出版社,2000:1662—1665.
  • 2Gary R,Davis L.Diastolic heart failure[J] .Heart Lung,2008,37(6):405-416.
  • 3Bemstein D,Jardo GF,Zhao MM.The role of 3-adrenergic receptors in heart failure:Differential regulation of cardiotoxieity and cardiopmtection[J] .Pmg Pediatric Cardiology,2011,31:35-38.
  • 4Adlbrecht C,Hulsmann M,Strunk G,et al.Prognostic value of plasma midregional pro-adrenomedullin and Cterminal-proendothelin-1 in chronic heart failure outpatients[J] .Eur J Heart Fail,2010,11:361-366.
  • 5TESTA M, YEH M, LEE P, et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension [J]. J Am Coll Cardiol, 1996, 28(4): 964- 971.
  • 6VON HAEHLING S, SCHEFOLD J C, LAINSCAK M, et al. Inflammatory biomarkers in heart failure revisited: much more than innocent bystanders [J]- Heart Fail Clin, 2009, 5 (4) : 549-560.
  • 7ANKER S D, VON HAEHLING S. Inflammatory mediators inchronic heart failure : an over-view [J]. Heart, 2004, 90 (4) : 464-470.
  • 8GULLESTAD L, AUKRUST P. Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches [J]. Am J Cardiol, 2005, 95 (IlA) : 17C -23C ; discussion 38C-40C.
  • 9CUMMINGS J R, AHMAD T, GEREMIA A, et al. Contribution of the novel inflammatory bowel disease gene IL23R to disease susceptibility and phenotype [J]. Inflamm Bowel Dis, 2007, 13(9): 1063-1068.
  • 10TREMELLING M, CUMMINGS F, FISHER S A, et al. IL23R variation determines susceptibility but not disease phenotype in inflammatory bowel disease [J]. Gastroenterology, 2007, 132 (5) : 1657-I664.

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部